ArticleBiochemical genetics2026
Decoding the Transcriptional Complexity of the Human BRCA2 DNA Repair Gene Using Hybrid-seq.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BRCA2 plays a pivotal role in DNA repair and tumor suppression, with its dysregulation linked to breast and gynecological cancers. Despite the importance of BRCA2, its transcriptional complexity remains poorly understood due to the gene's size and intricate alternative splicing patterns. This study aims to comprehensively characterize the BRCA2 transcriptional landscape in breast, ovarian, and cervical cancers using a hybrid sequencing approach. A novel hybrid-seq method combining long-read nanopore sequencing and short-read NGS was applied to analyze BRCA2 transcripts from cancerous cell lines. Expression patterns were evaluated using the transcript-per-million (TPM) normalization method, and open reading frames (ORFs) of the identified transcripts were in silico characterized. Sequencing analysis led to the identification of 50 novel splice variants (BRCA2 sv.7-sv.56), expanding the known transcript repertoire of BRCA2 gene. Notably, transcript variants sv.9, sv.15, and sv.49 exhibited significant expression in breast and ovarian cancers, while others, such as sv.29 and sv.40, were specific to individual cancer types. Five cryptic exons (N1-N5) were unveiled, contributing to 10 unique splice variants. In silico analysis revealed that 19 novel transcripts retained coding potential, with some encoding BRCA2 isoforms harboring key functional domains. The identification of novel BRCA2 transcripts underscores the complexity of its regulation in cancer. These findings provide insights into the gene's potential role in tumorigenesis and highlight candidates for targeted therapies and diagnostic biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.